Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc

Registered Charity 3104


Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.


ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

Pfizer halts late-stage Lyrica study

Sunday 13 May 2012




ProHealthPfizer halts late-stage study into new Lyrica use

Associated Press
May 04, 2012

Pfizer halted a late-stage study of its second-best selling drug, Lyrica, as a possible treatment for a nerve pain in HIV patients.

The world’s largest drugmaker said Friday it was studying the drug in patients with HIV neuropathy, which is nerve damage characterized by burning pain that usually starts in the feet. An early analysis of study data showed that pain symptom improvements were nearly identical to those patients treated with a placebo.

No safety concerns were raised in the study, and Pfizer said it will continue to analyze the initial results.

Lyrica is already approved in the United States to treat diabetic nerve pain, pain after shingles, fibromyalgia and for some seizures in adults with epilepsy. It brought in $955 million in sales in the first quarter for the New York drugmaker, behind only cholesterol fighter Lipitor’s $1.4 billion.

Pfizer lost the U.S. patent protecting Lipitor last fall, and Lyrica could overtake the drug to become Pfizer’s top seller, especially after several generic drugmakers enter the market at the end of this month with their own versions of Lipitor.

Lyrica’s revenue increased 16 percent in the recently completed first quarter, while Lipitor sales plunged 42 percent.

Shares of Pfizer Inc. fell 23 cents to $22.38 in afternoon trading while the Standard and Poor’s 500 index dropped more than 1 percent.


The above originally appeared here.


Arrow right

More Fibromyalgia News



blog comments powered by Disqus

Previous Previous Page